spacer
home > white papers > Financial implications of off-site visits in clinical research, perception versus reality - Illingworth Research
WHITE PAPERS
logo_IllingwortE.jpg

Illingworth Research

phone +44 (0)1625617447
email info@illingworthreseach.com
web http://www.illingworthresearch.com
email Illingworth Research Ltd, Suite 5, Silk House, Park Green, Macclesfield, Cheshire, SK11 7QJ, England

Financial implications of off-site visits in clinical research, perception versus reality

The concept of patient centricity is still relatively new within clinical trials. For too long, the most important person in the trial has been overlooked… the patient. Here, we explore the benefits of conducting a more patient-centric trial for the patient, site and sponsor through mobile, or ‘off-site’ visits. These advantages are much greater than purely financial, although the financial implications of running a more patient-focused clinical trial may previously have deterred some from this approach. Home nursing in clinical trials continues to be thought of as a high value “premium” service, which many sponsors decline in an attempt to remain within budget for the trial. However, is the actual cost of off-site nursing more expensive than the traditional site model?
Financial implications of off-site visits in clinical research, perception versus reality
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Pharmaceutical companies go temporary to overcome pandemic challenges

Fast-tracking clinical trials, optimising energy intensive processes and improving yield are three ways in which temporary equipment is helping pharmaceutical companies amid the COVID-19 pandemic.
More info >>


White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>


Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement